K-783-0308

N/A

Report date: 2026/01/19 17:49:21
NME

Base Information

Drug NameK-783-0308
Drug Alias NameK-783-0308
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMAP kinase-interacting serine/threonine-protein kinase 2 inhibitorsTyrosine-protein kinase receptor FLT3 inhibitors
TargetsMAP kinase-interacting serine/threonine-protein kinase 2Tyrosine-protein kinase receptor FLT3
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryTaiwan
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesTaipei Medical University
China Registration ClassN/A

Develop Information

Active CompaniesTaipei Medical University
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A